Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors

被引：0
|
作者：
Mamdani, Hirva [1 ]
Jalal, Shadia I. [2 ]
机构：
[1] Wayne State Univ, Karmanos Canc Inst, 4100 John R, Detroit, MI 48201 USA
[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
TRK; ENTRECTINIB; INHIBITOR; ONCOGENE; ROS1;
D O I：
10.21037/atm.2019.06.41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas A Review
    Haddad, Robert
    Elisei, Rossella
    Hoff, Ana O.
    Liu, Zhiyan
    Pitoia, Fabian
    Pruneri, Giancarlo
    Sadow, Peter M.
    Soares, Fernando
    Turk, Andrew
    Williams, Michelle D.
    Wirth, Lori J.
    Cabanillas, Maria E.
    JAMA ONCOLOGY, 2023, 9 (08) : 1132 - 1141
  • [2] Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans
    Zhou, Katherine I.
    Vashistha, Vishal
    Guo, Aixia
    Ahmed, Sara
    Kelley, Michael J.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [3] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers
    Drilon, Alexander
    Tan, Daniel S. W.
    Lassen, Ulrik N.
    Leyvraz, Serge
    Liu, Yongmei
    Patel, Jyoti D.
    Rosen, Lee
    Solomon, Benjamin
    Norenberg, Ricarda
    Dima, Laura
    Brega, Nicoletta
    Shen, Lin
    Moreno, Victor
    Kummar, Shivaani
    Lin, Jessica J.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [4] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
    Drilon, A.
    Lin, J.
    Lassen, U.
    Leyvraz, S.
    Liu, Y.
    Patel, J.
    Rosen, L.
    Solomon, B.
    Norenberg, R.
    Dima, L.
    Brega, N.
    Shen, L.
    Moreno, V.
    Kummar, S.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1125 - S1126
  • [5] EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
    Perreault, Sebastien
    Doz, Francois
    Geoerger, Birgit
    Nysom, Karsten
    Ora, Ingrid
    Boni, Valentina
    Chisholm, Julia
    DuBois, Steven G.
    Gerber, Nicolas U.
    Goto, Hiroaki
    Grilley-Olson, Juneko E.
    Hansford, Jordan R.
    Kang, Hyoung Jin
    Capra, Michael
    Schulte, Johannes H.
    Stefanowicz, Joanna
    Tahara, Makoto
    Ziegler, David S.
    Norenberg, Ricarda
    Dima, Laura
    De La Cuesta, Esther
    Laetsch, Theodore W.
    van Tilburg, Cornelis M.
    NEURO-ONCOLOGY, 2021, 23 : 42 - 42
  • [6] Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset
    Boni, V.
    Drilon, A.
    Deeken, J.
    Garralda, E.
    Chung, H.
    Kinoshita, I.
    Oh, D.
    Patel, J.
    Xu, R.
    Norenberg, R.
    Brega, N.
    Dima, L.
    Hong, D.
    Berlin, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S214 - S215
  • [7] Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
    Lemelle, Lauriane
    Guillemot, Delphine
    Hermann, Anne-Laure
    Gauthier, Arnaud
    Carton, Matthieu
    Corradini, Nadege
    Rome, Angelique
    Berlanga, Pablo
    Jourdain, Anne
    Cardine, Aude Marie
    Jannier, Sarah
    Boutroux, Helene
    Defachelles, Anne Sophie
    Aerts, Isabelle
    Geoerger, Birgit
    Karanian, Marie
    Doz, Francois
    Brisse, Herve J.
    Schleiermacher, Gudrun
    Delattre, Olivier
    Pierron, Gaelle
    Orbach, Daniel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (08) : 865 - 874
  • [8] Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors
    Bokemeyer, Carsten
    Vassal, Gilles
    Italiano, Antoine
    De la Cuesta, Esther
    Hiemeyer, Florian
    Fellous, Marc
    Marian, Marisca
    JCO PRECISION ONCOLOGY, 2021, 5 : 1458 - 1465
  • [9] Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.
    Perreault, Sebastien
    van Tilburg, Cornelis Martinus
    Geoerger, Birgit
    Nysom, Karsten
    Ora, Ingrid
    Gavrilovic, Igor T.
    Norenberg, Ricarda
    Dima, Laura
    De La Cuesta, Esther A.
    Drilon, Alexander E.
    Doz, Francois P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
    Doz, Francois
    van Tilburg, Cornelis M.
    Geoerger, Birgit
    Nysom, Karsten
    Ora, Ingrid
    Boni, Valentina
    Chisholm, Julia
    Chung, Hyun Cheol
    DuBois, Steven G.
    Gallego Melcon, Soledad
    Gerber, Nicolas U.
    Goto, Hiroaki
    Grilley-Olsen, Juneko E.
    Hansford, Jordan R.
    Hong, David S.
    Italiano, Antoine
    Kang, Hyoung Jin
    Capra, Michael
    Schulte, Johannes H.
    Stefanowicz, Joanna
    Tahara, Makoto
    Ziegler, David S.
    Gavrilovic, Igor T.
    Norenberg, Ricarda
    Dima, Laura
    De La Cuesta, Esther
    Laetsch, Theodore W.
    Drilon, Alexander
    Perreault, Sebastien
    NEURO-ONCOLOGY, 2021, 23 : 73 - 74
12345